Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

✍ Scribed by J.M Extra; F Cognetti; D Maranichi; R Snyder; L Mauriac; M Tubiana-Hulin; S Chan; D Grimes; A Anton; M Marty

• Book ID: 118622190
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 348 KB
• Volume: 2
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(04)90842-7